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Abstract
Background: Thyroid papillary microcarcinoma (TPM) is defined according to WHO criteria as a thyroid tumor smaller
than 1–1.5 cm. TPMs are encountered in 0.5–35.6 % of autopsies or surgical specimens where carcinoma had been
unsuspected. The purpose of the present study was to evaluate patients who had TPMs in terms of clinical findings,
histopathological features and immunohistochemical evidence of expression of the tumor suppressor gene p53.
Methods: A total of 44 patients with TPMs less than 1.0 cm in diameter were included in the study. The patients were
evaluated clinically and the tumors were evaluated in terms of their histopathological and immunohistochemical features,
including expression of p53.
Results: The female/male ratio was 2.8/1, and the median age at time of diagnosis was 49 years (range 20–71 years). The
maximum diameter of the smallest focus was 0.1 mm, and that of the largest was 10 mm microscopically. The mean
diameter of all tumors was 5.7 mm. There was no correlation between tumor size and age or gender. Of the TPMs, 72
% were found in the right lobe, 24 % in the left lobe and 4 % in the isthmus. Fine-needle aspiration biopsy provided the
diagnosis of TPM in only 43.2 % of the patients. All patients were treated with surgery, with 20 undergoing conservative
surgery, i.e. lobectomy or isthmusectomy, and 24 undergoing total thyroidectomy. Frozen section provided the diagnosis
of TPM in only 56.8 % of the patients. We found lymphocytic thyroiditis in 13.6% of patients, follicular variants in 11.9%,
capsular invasion in 26.8%, lymph node involvement in 11.9%, soft tissue metastases in the neck in 12.1% and multifocality
in 31.7 %, and none of these were related to age or gender (p > 0.05). No distant metastases were observed during
approximately 10 years of follow up. We found p53 positivity in 34.5 % of TPM tumors. However, p53 expression was
not statistically related to age or gender.
Conclusion: Our findings imply that TPMs may not be entirely innocent since they are associated with signs of poor
prognosis such as capsular invasion, multifocal presentation, lymph node involvement and p53 positivity. Therefore, TPMs
should be evaluated and followed like classical papillary cancers.
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Thyroid papillary microcarcinoma (TPM), also known as
occult papillary carcinoma (OPC), is usually defined as a
thyroid tumor smaller than 1–1.5 cm [1,5]. The term
"occult thyroid papillary carcinoma" had been used
before the WHO proposed a major diameter of 1 cm for
occult papillary carcinoma, and renamed it as microcarci-
noma [6]. Despite this proposal, different terms are cur-
rently used to define this thyroid cancer such as small,
tiny, minute, minimal or incidental thyroid papillary can-
cer [7,10].
TPMs are found at rates of 0.5–35.6 % at autopsy or in sur-
gical specimens where carcinoma had been unsuspected
[11,18]. Some authors suggest that small tumors are very
unlikely to be clinically significant even though up to 60
% of these lesions are associated with lymph node metas-
tases which may be their presenting features [19,20].
TPMs that either have lymph node metastases or are
multifocal with extracapsular invasion may be associated
with lung metastases. Such cases are rare but they have sig-
nificant morbidity and mortality [20,21]. Other authors
take it as widely accepted that the recurrence and mortal-
ity risks of microcarcinomas are low [22,24].
Given these somewhat mixed views regarding the clinical
importance of TPMs, it seems desirable to study these
tumors in detail, particularly in terms of any biochemical
markers they exhibit. One such marker is the protein
product of p53, a tumor suppressor gene. Mutations in or
deletions of the p53 gene are among the most frequently
detected genetic changes in human cancers [25,26]. The
gene itself is located on the short arm of chromosome 17
[26]. The p53 protein is capable of inhibiting cell prolifer-
ation and transformation [27,28]. Several studies have
shown a correlation between mutated p53 gene expres-
sion and degree of tumor differentiation [29,30]. It has
also been reported that p53 gene expression is an indica-
tor of poor prognosis, and might be important in the
future for planning the treatment of TPMs [31,32].
The purpose of the present study was to evaluate patients
with TPMs in terms of clinical findings, histopathological
features and immunohistochemical evidence of p53
expression, and to describe the relations between these.
Patients and methods
We reviewed the clinical records of 255 consecutive
patients who underwent surgery for thyroid cancer
between 1994 and 2002 at Ankara University Hospital in
Ankara, Turkey. Of these patients, 44 had tumors that
were less than 1.0 cm in diameter, and these tumors were
classified as microcarcinoma. Of these 44 patients, 29 had
pathological preparations that we were able to stain for
p53 expression. The specimens of the 15 other patients
could not be stained for various reasons, including inade-
quate pathological slides. This retrospective study was per-
formed in accordance with the ethical requirements of our
institution. All histopathologic and cytologic materials
were reviewed by the same pathologist and were evaluated
according to WHO recommendations [6].
The variables examined in this study included age and
gender of the patient, tumor size, histological features
(multifocality, invasion of the thyroid capsule, etc.), the
presence of distant or regional metastases and the expres-
sion of p53 protein.
To detect p53 gene expression immunohistochemically,
we used a monoclonal antibody that reacts with both
mutant and wild type p53 protein (clone DO7+BP53-12,
Neomarkers, CA, USA). Sections 4–6 μm thick were cut
from tissue fixed with 10 % buffered formalin, embedded
in paraffin blocks and treated with xylene for deparaffini-
zation and were rehydrated in decreasing alcohol concen-
trations. Antigen retrieval was performed by heating
samples in citrate buffer (pH 7.0) in a pressure cooker.
Endogenous peroxidase activity was blocked by H2O2. A
streptavidin biotin horseradish peroxidase system with a
computerized staining apparatus (Ventana, Nexus) was
used for staining procedures. Antibody dilution was
1:100. Diaminobenzidine (DAB) was used as a chro-
mogen and counterstaining was performed with hema-
toxylin. A larynx carcinoma with known p53 expression
served as the positive control. For the negative control, the
procedures were the same but PBS was substituted for the
primary antibody. The slides were evaluated by light
microscopy, and brown nuclear staining was accepted as
positive. The most extensively stained area was examined
and the percentage of positively stained tumor cells was
estimated.
Statistical analyses were performed with SPSS v.11.0 soft-
ware (SPSS Inc., Chicago, USA).
Results
Among the 44 patients in the study, the female to male
ratio was 2.8/1, and the median age at time of diagnosis
was 49 years (range 20–71 years). Mean follow-up period
of the patients was approximately 10 years. None of the
patients had previously received radiation therapy
directed at cervical lymph nodes and none had a family
history of thyroid cancer.
The maximum diameter of the smallest focus was 0.1 mm,
and that of the largest was 10 mm microscopically. The
mean diameter of all tumors was 5.7 mm, and the mean
diameters in males and females were 5.4 mm and 5.8 mm,
respectively. When the patients were classified as younger
or older than 50 years, the mean diameter of TPMs was 5.5Page 2 of 6
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Tumor size was not related to age or gender (p > 0.05). Of
the TPM foci, 72 % were found in the right lobe, 24 % in
the left lobe and 4 % in the isthmus.
Table 1 compares fine needle aspiration biopsy (FNAB)
and frozen section in terms of detectability for TPM in our
patients. FNAB provided the diagnosis of papillary carci-
noma in only 43.2 % of the TPM tumors. All patients
underwent surgery. Conservative methods, i.e. lobectomy
and isthmusectomy, were used in 20 patients and total
thyroidectomy was performed in 24 patients. Frozen sec-
tion studies provided the diagnosis of TPM in only 56.8 %
of the patients that were examined by frozen section. Of
the patients with malignancy demonstrated by FNAB, 6.8
% were diagnosed with benign disease on frozen section.
Following surgery, the 24 patients who had bilateral total
thyroidectomy received I131 ablation therapy. The dosage
of I131 ranged from 75 to 200 mCi. Thyroid hormone
replacement therapy (LT4) was continuously adminis-
tered to these patients as well as to the 20 patients who
had received lobectomy or isthmusectomy. The dosage of
LT4 ranged from 100 to 175 μg.
Table 2 shows the histopathologic and other features of
the tumors. Due to their small size most TPMs were not
detected grossly. All tumors exhibited the characteristic
features of papillary carcinoma such as ground-glass
nuclei with nuclear grooves and occasional nuclear inclu-
sions. We found lymphocytic thyroiditis in 13.6% of
patients, follicular variants in 11.9%, capsular invasion in
26.8%, lymph node involvement in 11.9%, soft tissue
metastases in the neck in 12.1% and multifocality in 31.7
%, and none of these were related to age or gender (p >
0.05). During approximately 10 years of follow-up, no
distant metastases were observed and there were no
deaths.
We found p53 positivity in 34.5 % of the TPM tumors.
There was no correlation between p53 expression and sex,
age, histological variant of tumors, capsular invasion,
multifocality or presence of local or regional lymph node
metastases (p > 0.05) (Table 2).
Discussion
When we examine the cases of TPM in our patients and in
the literature, we find that despite their small size, TPMs
are not biologically innocent in all cases and may show
capsular invasion, multifocality, regional lymph node
metastases and p53 protein positivity at the time of diag-
nosis. These features associated with a portion of TPMs are
the poor prognostic factors for differentiated thyroid
malignancies (DTC). TPMs might therefore need to be
evaluated and followed in the same way as classical thy-
roid papillary carcinomas.
Among our patients, females appeared to be more fre-
quently affected, as is the case in other types of papillary
carcinoma. Our female to male ratio was 2.8/1, similar to
that in Salvadori's microcarcinoma study [34]. Kasai and
Sakamoto have reported an even higher female to male
ratio of 9/1 in their series [7]. In contrast, some authors
reported that OPC was more common in men than in
women, although non-occult papillary carcinoma was
more common in women [12,35]. These latter findings
favor the view that OPC is a different clinical entity and
not the early stage of non-occult papillary carcinoma.
The median age at time of diagnosis of TPM was 49 years
in our patients. Our patients' ages ranged from 20 to 71, a
wide range similar to those previously reported in the lit-
erature [14,15].
With fine needle aspiration biopsy (FNAB) of the thyroid
we were able to detect malignancy in only 43.8 % of our
TPM tumors. This ratio is slightly lower than some previ-
ously reported rates, which range from 35.8 % to 55.5 %
[36,41,46]. The reason for our lower rate of carcinoma
detection with FNAB may be the smaller sizes of the
tumors we have examined. Tumors with diameters less
than 10 mm have been evaluated in our present study
whereas tumors up to 15 mm in diameter have been
included in most of the previous studies. Still, our rate is
more or less close to the 49.3 % rate of carcinoma detec-
tion in OPC with ultrasound-guided FNAB reported by
Jen Der Lin et al [36]. The rate of detection of carcinoma
in frozen section examination is also low (57 %) in our
study. Small tumor size might be responsible for this as
well. In the study by Jen Der Lin et al., malignancy was
detected in 73 % of the OPC cases on frozen section exam-
ination [36].
Table 1: Comparison of FNAB and frozen section in terms of their detection of TPM
FNAB (% of patients) Frozen section (% of patients) Postoperative pathology (% of 
patients)
TPM 43.2 56.8 100
Follicular variant 0 0 11.9Page 3 of 6
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was observed in 26.8 % of our patients. Salvadori et al.
reported an incidence of 15.2 % of capsular invasion in a
series that included tumors larger than those evaluated in
our study [34]. Furmanckuk et al. reported that one
patient out of 10 with papillary or mixed papillary-follic-
ular OPC had capsular invasion [16]. Harach et al.
reported a 17 % rate of capsular invasion in their series
[12]. They observed a statistically significant association
between tumor size and capsular invasion, larger tumors
being more likely to invade the capsule [12].
The occurrence of multiple foci of carcinoma in OPC is
thought to be due to intrathyroidal tumoral invasion
through lymphatics rather than neoplastic transformation
of multiple clones of cells located in various parts of the
thyroid [37]. Multiple carcinomatous foci can sometimes
be observed in both lobes of the thyroid [3,12,14,15].
Multiple foci of papillary carcinoma were identified in
31.7 % of TPM tumors in our series. The incidence of
multifocality in OPC has been reported as 35.6% by Har-
ach [12], 30.4 % by Yamamoto [14], 20.6 % by Pelizzo
[15], 31.5 % by Furmanckuk [16], and 23.6 % by Salva-
dori [34]. Hazard has noted that multifocality is associ-
ated with metastases [38]. A small tumor can therefore be
multifocal and carry the risk of metastasis. No relation-
ship has been reported, so far, between the multiplicity of
tumors and age or gender, and we found no such relation
in our patients.
We found lymphocytic infiltration within the tumor
stroma or around the tumor foci in six patients (13.6 % of
TPM tumors). Harach et al. have reported a rate of 27.7 %
for lymphocytic reaction within the tumor stroma or
around the invading tumor islands [12]. Such lym-
phocytic infiltration was associated with invasive OPC
and larger tumors, and it was thought to represent host
reaction to tumor. The occurrence of lymphocytic infiltra-
tion limited to tumor periphery therefore seems unrelated
to lymphocytic thyroiditis [12]. However, Hirabayashi
and Lindsay have reported a higher than expected fre-
quency of non-occult papillary carcinoma in patients with
thyroiditis [39], and it has also been reported that the
presence of lymphocytic thyroiditis around tumors indi-
cates a good prognosis [40].
Lymph node metastases are characteristic features of all
types of papillary carcinoma including OPC. However,
they are of doubtful clinical significance. They are thought
to indicate early recurrence and poor prognosis by some
authors [31,42]. On the other hand, other investigators
report that regional lymph node metastases do not affect
survival [43,45]. Regional lymph node metastases were
detected in 11.9 % of our patients and this is an incidence
that is well within previously reported ranges. Frequencies
of lymph node metastases in OPC have been reported as
zero by Pelizzo et al. [15], as 0.3 % by Yamamoto et al
[14], as 23 % by Hazard et al. [38], as 39 % by Woolner et
al. [41], as 40 % by Hubert et al. [10], and as 42 % by
Kasai et al. [7]. The highest reported frequency of lymph
metastases is 70.8 % in the study by Salvadori et al. on
OPC patients with tumor sizes less than 15 mm [34].
The presence of distant metastases indicates a poor prog-
nosis for OPC [31]. Although distant metastases are rare
in OPC as deduced from follow-up [34] or from findings
Table 3: Persentages in p53 positive and p53 negative patients according to histopathologic features.
p53 positive n (%) p53 negative n (%) Total n
Lymphocytic thyroiditis 2 (33.3) 4 (66.7) 6
Follicular variant 2 (40.0) 3 (60.0) 5
Capsular invasion 5 (45.5) 3 (54.5) 11
Lymph node involvement 3 (60.0) 2 (40.0) 5
Soft tissue metastases in the neck 4 (66.7) 2 (33.3) 5
Multifocality 7 (53.8) 6 (46.2) 13
Table 2: Histopathologic and other features of the tumors in this study
(n) %
Lymphocytic thyroiditis 6(44) 13.6
Follicular variant 5(42) 11.9
Capsular invasion 11(41) 26.8
Lymph node involvement 5(42) 11.9
Soft tissue metastases in the neck 5(41) 12.1
Distant metastases 0 0
Multifocality 13(41) 31.7
p53 positivity 10(29) 34.5Page 4 of 6
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pleura, vertebral column, pericardium, cerebrum, femur,
humerus and mediastinum have been reported [1,46,53].
The smallest reported tumor with distant metastases was
3 mm in diameter [46]. No distant metastases were
present in our patients with TPM during a follow-up
period of approximately 10 years.
Similar to previous reports [14,15] tumors were located in
the right lobe in 72 % of our patients, in the left lobe in
24 %, and in the isthmus in 4 %. Although the signifi-
cance of this pattern of uneven distribution has not yet
been clarified, nodules located in the right thyroid lobe
may deserve a more detailed evaluation.
Tumor size has been reported as an important prognostic
factor in papillary and follicular carcinomas of the thyroid
[31]. In two autopsy series the mean diameter of occult
thyroid carcinoma was 1.7 mm and 1.98 mm, respectively
[14,16]. Tumor diameters in our series ranged from 1 to
10 mm (mean 5.7 mm). No association was found
between tumor size and age or gender in those autopsy
series [14,16]. The same was true in our series. One of the
larger recent studies reported that approximately one in
four patients with a papillary thyroid cancer no more than
1.5 cm in size developed persisting or relapsing disease
after surgery [62].
Over-expression of p53 and mutations in the p53 gene are
more frequent in poorly differentiated and anaplastic car-
cinomas than in well-differentiated papillary and follicu-
lar carcinomas [32,54,63]. Also, p53 gene expression is
reported to be a significant and independent prognostic
factor for cause-specific and crude survival in these
patients [31,32]. Anaplastic changes following insuffi-
cient radioiodine therapy have been shown to be associ-
ated with p53 gene mutation in differentiated thyroid
carcinoma [64]. There is a higher rate of p53 gene muta-
tion in the tall cell variant of papillary thyroid carcinoma
than in the common variant [65]. Immunohistochemical
detection of p53 protein by means of prolonged half-life
is thought to be associated with the occurrence of p53
gene mutations since the prolongation of the protein's
half-life has been regarded as a direct consequence of
structural changes attributable to missense point muta-
tions [25]. More recent investigations have demonstrated
that wild type p53 can be stable up to approximately 24
hours [33]. The mutated p53 protein can remain present
in tissues for longer than 24 hours whereas the normal
protein cannot. Of our patients, only 34.5 % tested posi-
tive for p53 and this was not significantly associated with
age, gender, capsular invasion, lymph node metastases,
multifocality, tumor location, histologic variant of tumor,
or tumor diameter.
Conclusion
Our findings in this study imply that TPMs may not be
innocent since they can be associated with indicators of
poor prognosis such as capsular invasion, multifocal pres-
entation, lymph node involvement and p53 positivity.
Therefore, thyroid papillary microcarcinomas should be
evaluated and followed like other papillary cancers. In
order to reach a clearer understanding of the relationships
between p53 positivity and TPM, p53 gene mutations
should be detected by using PCR methods, and clinical
outcomes of these mutations should be evaluated in lon-
gitudinal studies in the same patients.
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